Mesa Laboratories Acquires Agena Bioscience

Agilent Technologies Acquires Avida Biomed

January 4, 2023

Biotechnology

Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

ProPhase Labs Acquires Nebula Genomics

August 11, 2021

Biotechnology

ProPhase Labs, through its newly formed subsidiary ProPhase Precision Medicine, completed the acquisition of Nebula Genomics, a privately owned whole‑genome sequencing and personal genomics company. The deal (approximately $14.6 million in a mix of cash and ProPhase common stock) will integrate Nebula’s whole genome sequencing capabilities and DTC platform into ProPhase’s CLIA-certified molecular testing laboratories to expand diagnostic and consumer genomics offerings.

Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones

July 27, 2021

Biotechnology

Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.

Mesa Laboratories Acquires Gyros Protein Technologies

October 31, 2019

Biotechnology

Mesa Laboratories (NASDAQ: MLAB) acquired Gyros Protein Technologies Holding AB (GPT) from AP6 (Sixth Swedish National Pension Fund), Ampersand Capital Partners and individual shareholders for $180 million in cash. The acquisition, which establishes Mesa's new Biopharmaceutical Development platform, adds GPT's immunoassay and peptide synthesis instruments and consumables and is expected to contribute roughly $37–$40 million of revenue in the first 12 months (about 55% recurring).

LabCorp Acquires MNG Laboratories from HealthEdge

March 4, 2019

Healthcare Services

LabCorp has acquired MNG Laboratories, an Atlanta-based clinical diagnostic provider specializing in neurogenetics and next-generation sequencing, from HealthEdge Investment Partners' Fund II. The acquisition expands LabCorp’s neurology and neurogenetics testing capabilities and makes MNG’s testing services available through LabCorp’s Covance drug development business.